Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19

Melton, James D.; Wilson, Kayla; Blind, Fred; Barbera, Andrew R. La; Bhisitkul, Donna M.; Hasara, Shannon; Homa, Karen; Karp, Juliana; Escowitz, Hal; Haber, Todd; Degroot, Diana; Anderson, Jonathan; DeLeon, Jason; Santos, Jesse De Los; Faviere, Donna; Fuell, Joanne; Gillespie, Rita; Glueck, Jesse; Reeber, Cliff; Rhodes, David; Rodriguez, Vashun

doi:10.1016/j.ajem.2021.08.032

Cited by 3 publications

(2 citation statements)

References 3 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rates of infusion reaction ranged from 1.0% to 2.3%. Subsequent observational studies showed similar results, ranging from 0.8% to 13.7% depending on study definitions and population [23–25,29,32 ▪ ,72,73]. Anaphylactic reactions are rare, though have also been reported [39 ▪▪ ].…”

Section: Safetymentioning

confidence: 73%

Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Yetmar

Bhaimia

Razonable

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewCoronavirus disease-2019 (COVID-19) disproportionately causes severe outcomes in solid organ transplant recipients (SOTR). Antispike monoclonal antibodies have been authorized for therapy and prophylaxis for COVID-19. Here, we review the current state of antispike monoclonal antibodies and their role for SOTRs. Recent findingsBamlanivimab with or without etesevimab, casirivimab-imdevimab and sotrovimab have reduced the rates of hospitalization and severe disease in high-risk patients with mild-to-moderate COVID-19. Multiple retrospective studies have also demonstrated monoclonal antibodies are effective in SOTR populations. However, the evolution of resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concerns has resulted in revocation of the authorization of bamlanivimab with or without etesevimab, and casirivimab-imdevimab as treatment and postexposure prophylaxis (PEP). Sotrovimab and bebtelovimab are currently authorized for treatment of the predominant circulating SARS-CoV-2 B.1.1.529 (Omicron), but not as pre or PEP. Tixagevimab--cilgavimab, a long-acting antibody combination preparation, is authorized for preexposure prophylaxis in high-risk immunocompromised populations, including SOTRs, who are less likely to mount an effective immune response following vaccination series and booster.

show abstract

Section: Safetymentioning

confidence: 73%

Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Yetmar

Bhaimia

Razonable

2022

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

show abstract

“…As these therapeutic agents became readily available, clinicians and researchers embarked on comprehensive investigations into their impact on hospitalization rates and mortality outcomes. In spring 2021, bamlanivimab was associated with reduced rehospitalizations and, in most cases, mortality within 28 days [9,10,11,12]. Later, in the fall of 2021, sotrovimab use also seemed to decrease odds of hospitalization and mortality [13,14].…”

Section: Introductionmentioning

confidence: 99%

Outcomes of Monoclonal Antibody Use in Patients with COVID-19 (Preprint)

Huber,

Schnitzer,

Barry

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Since early 2021, monoclonal antibody (mAb) therapy has emerged as an efficacious intervention for patients with mild-to-moderate COVID-19 infections, particularly those at high risk of progressing to more severe infections. With favorable results from clinical trials, the U.S. Food and Drug Administration (FDA) issued Emergency Use Authorizations for a series of mAb treatments. As these therapeutic agents became readily available, clinicians and researchers embarked on comprehensive investigations into their impact on hospitalization rates and mortality outcomes. OBJECTIVE This study delves deeper into the effectiveness of accessible mAb therapies and their synergistic interactions with COVID-19 vaccinations in mitigating rehospitalization and mortality over a span of 19 months, within the encompassing landscape of greater Seattle in western Washington. METHODS We conducted an IRB-approved retrospective chart review of non-hospitalized adult patients who presented to emergency departments (ED) in the greater Seattle area from March 2021 through October 2022, exhibiting with mild-to-moderate COVID-19 infections and met eligibility criteria for monoclonal antibody therapy, having at least one of the following active comorbidities: arrythmia, cancer, cardiovascular dysfunction, diabetes, immunosuppression, obesity, renal dysfunction, a respiratory disorder, and/or tobacco use. We compared outcomes of patients who were treated with monoclonal antibodies to eligible patients who were not treated. Primary outcomes were rates of 28-day rehospitalization and all-cause hospital mortality. Secondary outcomes were rates of hospital inpatient admission, intensive care unit admission, and necessity for mechanical ventilation. We used propensity score matching and logistic regression models to isolate the effect of monoclonal antibody treatment on the outcome variables controlling for demographic characteristics and comorbidities. All statistical analyses were done in R Studio, and the MatchIt package was used for propensity score matching. RESULTS A total of 21,139 patients were included in the analysis. In the matched cohorts (mAb treated: N = 1,349; untreated: N = 1,349), mAb treatment was associated with reduced significantly odds of 28-day rehospitalization (adjusted odds ratio [aOR] 0.66, [95% confidence interval (CI)] 0.49-0.87), P = 0.004), mortality (adjusted odds ratio [aOR] 0.32, [95% confidence interval (CI)] 0.19-0.51), P < 0.001), and inpatient admissions (adjusted odds ratio [aOR] 0.43, [95% confidence interval (CI)] 0.31-0.61), P < 0.001). CONCLUSIONS From March 2021 through October 2022, monoclonal antibodies emerged as a pivotal factor in significantly reducing the incidence of rehospitalization, mortality, and inpatient admission amongst patients with mild-to-moderate COVID-19 infections in western Washington. Our study contributes real-world evidence to the medical literature, reaffirming the efficacy of monoclonal antibodies as a therapeutic option for outpatients with mild-to-moderate COVID-19 who are at an increased risk of developing severe infection. In light of the evolving landscape of the COVID-19 pandemic, marked by changing variants, the efficacy of individual mAb agents should continue to be vigilantly evaluated.

show abstract

Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database

Zhao

Wang

Zhang

et al. 2022

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19

Cited by 3 publications

References 3 publications

Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Antispike monoclonal antibodies for prevention and treatment of coronavirus disease-2019 in solid organ transplant recipients

Outcomes of Monoclonal Antibody Use in Patients with COVID-19 (Preprint)

Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database

Contact Info

Product

Resources

About